CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases

CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases

CUZD1, the CUB, and zona pellucida-like domains-containing protein 1, is a newly identified antigen of pancreatic autoantibodies (PAB) giving a reticulogranular pattern in patients with inflammatory bowel diseases, and in particular Crohn’s disease. The exact mechanisms by which this pancreatic anti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christos Liaskos, Eirini I. Rigopoulou, Timoklia Orfanidou, Dimitrios P. Bogdanos, Christos N. Papandreou
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Series:	Clinical and Developmental Immunology
Online Access:	http://dx.doi.org/10.1155/2013/968041
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Flow Cytometric Detection of p38 MAPK Phosphorylation and Intracellular Cytokine Expression in Peripheral Blood Subpopulations from Patients with Autoimmune Rheumatic Diseases
by: Athanasios Mavropoulos, et al.
Published: (2014-01-01)

The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic Arthritis
by: Athanasios Mavropoulos, et al.
Published: (2013-01-01)

Apoptosis, Inflammatory Bowel Disease and Carcinogenesis: Overview of International and Greek Experience
by: Jannis Kountouras, et al.
Published: (2003-01-01)

Noninvasive markers of inflammatory bowel disease activity
by: A. V. Nikitin, et al.
Published: (2018-08-01)

Interleukin-15 (IL-15) and Anti-C1q Antibodies as Serum Biomarkers for Ectopic Pregnancy and Missed Abortion
by: Alexandros Daponte, et al.
Published: (2013-01-01)

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
by: Anna Pau, et al.
Published: (2025-01-01)

Nonsteroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
by: Ingvar Bjarnason, et al.
Published: (1993-01-01)

Novel Targets for Anti-Inflammatory Therapy in Inflammatory Bowel Disease
by: John L Wallace
Published: (1994-01-01)

Antioxidant and anti-inflammatory roles of tea polyphenols in inflammatory bowel diseases
by: Van-Long Truong, et al.
Published: (2022-05-01)

Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease
by: Weigang Shu, et al.
Published: (2019-01-01)

TRAF1 Gene Polymorphism Correlates with the Titre of Gp210 Antibody in Patients with Primary Biliary Cirrhosis
by: Agnieszka Kempinska-Podhorodecka, et al.
Published: (2012-01-01)

Inflammatory Bowel Disease with Cytoplasmic-Staining Antineutrophil Cytoplasmic Antibody and Extensive Colitis
by: Hugh James Freeman
Published: (1998-01-01)

Cancer Risk in Inflammatory Bowel Disease
by: Anders M Ekbom
Published: (1995-01-01)

Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo
by: Siva Charan Devanaboyina, et al.
Published: (2024-12-01)

Expression of Annexin-A1 and Galectin-1 Anti-Inflammatory Proteins and mRNA in Chronic Gastritis and Gastric Cancer
by: Yvana Cristina Jorge, et al.
Published: (2013-01-01)

The Influence of Physical Activity on Inflammatory Markers, Intestinal Microbiota Composition and Disease Activity in Inflammatory Bowel Disease
by: Paulina Jakubczyk, et al.
Published: (2025-01-01)

Inflammatory Myofibroblastic Tumor of the Breast
by: Christos Markopoulos, et al.
Published: (2015-01-01)

Increased urinary nitrite, a marker of nitric oxide, in active inflammatory bowel disease
by: Michael G. Goggins, et al.
Published: (2001-01-01)

Anti-LGI1 antibody autoimmune encephalitis. Clinical case presentation and literature review
by: A. Stašaitytė, et al.
Published: (2021-03-01)

Sex Differences Associated with Primary Biliary Cirrhosis
by: Daniel S. Smyk, et al.
Published: (2012-01-01)

Effectiveness of syndecan-1 as an adjunct diagnostic marker in small bowel injury: a report of two cases
by: Hideshi Okada, et al.
Published: (2025-01-01)

Novel anti-inflammatory properties of mannose oligosaccharides in the treatment of inflammatory bowel disease via LGALS3 modulation
by: Yaqi Du, et al.
Published: (2025-02-01)

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2024-10-01)

Monocyte Chemotactic Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities
by: Jian Lin, et al.
Published: (2020-01-01)

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
by: Toshio Shimizu, et al.
Published: (2025-01-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
by: Cui Zhang, et al.
Published: (2018-01-01)

Comparative Value of Simple Inflammatory Markers in the Prediction of Left Ventricular Systolic Dysfunction in Postacute Coronary Syndrome Patients
by: Panagiotis Aggelopoulos, et al.
Published: (2009-01-01)

Design of a humanized CD40 agonist antibody with specific properties using AlphaFold2 and development of an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
by: Kun Du, et al.
Published: (2025-02-01)

CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
by: Cristina Melero, et al.
Published: (2024-12-01)

Evaluation of Anti-HIV-1 Integrase and Anti-Inflammatory Activities of Compounds from Betula alnoides Buch-Ham
by: Prapaporn Chaniad, et al.
Published: (2019-01-01)

Anti-Inflammatory Effect of a Peptide Derived from the Synbiotics, Fermented Cudrania tricuspidata with Lactobacillus gasseri, on Inflammatory Bowel Disease
by: Jimyeong Ha, et al.
Published: (2020-01-01)

Circulating Inflammatory Markers Are Inversely Associated with Heart Rate Variability Measures in Type 1 Diabetes
by: Anne-Marie L. Wegeberg, et al.
Published: (2020-01-01)

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy
by: Panagiotis J. Vlachostergios, et al.
Published: (2012-01-01)

Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developability
by: Wei-Ching Liang, et al.
Published: (2024-12-01)

Neutrophils: From Inflammatory Bowel Disease to Colitis-Associated Colorectal Cancer
by: Chen T, et al.
Published: (2025-01-01)

Characterization of Human Colorectal Cancer MDR1/P-gp Fab Antibody
by: Xuemei Zhang, et al.
Published: (2013-01-01)

Synthesis and Anti-Inflammatory Activity of New Alkyl-Substituted Phthalimide 1H-1,2,3-Triazole Derivatives
by: Shalom Pôrto de Oliveira Assis, et al.
Published: (2012-01-01)

Small-Cell Lung Cancer with Positive Anti-NMDAR and Anti-AMPAR Antibodies Paraneoplastic Limbic Encephalitis
by: Sabina Boangher, et al.
Published: (2016-01-01)

Immunopathogenesis of inflammatory bowel diseases
by: Ye. A. Konovich, et al.
Published: (2013-09-01)